Beckley Psytech announces positive initial data from Phase IIa study of novel 5-MeO-DMT formulation BPL-003 for Treatment Resistant Depression
www.businesswire.com
Beckley Psytech Ltd, the private, clinical-stage biopharmaceutical company dedicated to improving the lives of people living with neuropsychiatric dis

TL;DR:

  • A single dose of DMT produced a fast antidepressant response in 55% of patients the day after dosing.

  • A durable antidepressant effect was also shown, with 55% of patients in remission from depression at day 29 and 45% in remission at day 85.

  • DMT demonstrated a short treatment duration, with acute effects resolving and patients deemed dischargeable within an average time of less than 2 hours.

  • DMT was generally well-tolerated with no serious adverse events reported.